Clinical trial
Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant…
NCT00107094 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00107094 |
|---|---|
| Title | Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer |
| Official title | An Open Label, Pilot Study of Dose-Dense Adriamycin Plus Cyclophosphamide (AC) Followed by ABI-007 as Adjuvant Therapy for Patients With Breast Cancer |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Abraxane |
| Enrollment | 30 |
| Start date | Mar 1, 2005 |
| First posted | Apr 6, 2005 |
| Last update posted | Jul 20, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: